Niacin: chemical forms, bioavailability, and health effects

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Metabolic Disorders

Background:

• Elevated low-density lipoprotein cholesterol (LDL-C) is a primary target for lipid-altering therapy to reduce cardiovascular disease (CVD) risk in dyslipidemia.
• Residual CVD risk persists even with controlled LDL-C, linked to other markers like low high-density lipoprotein cholesterol (HDL-C), high lipoprotein a, and hypertriglyceridemia.
• Niacin is a valuable therapeutic agent for managing high LDL-C, low HDL-C, high lipoprotein a, and hypertriglyceridemia.

Purpose of the Study:

• To assist healthcare professionals in selecting the most appropriate niacin formulation for specific therapeutic objectives.
• To provide a literature-based assessment of the risks associated with different niacin preparations.

Main Methods:

• Review of available literature on various niacin formulations and their therapeutic effects.
• Evaluation of risk profiles for different forms of niacin, including unbound niacin (free nicotinic acid, NA), extended-release NA, inositol hexanicotinate, and nicotinamide (niacinamide).

Main Results:

• Niacin addresses multiple lipid abnormalities beyond LDL-C, including HDL-C, lipoprotein a, and triglycerides.
• Different niacin forms (unbound NA, extended-release NA, inositol hexanicotinate, nicotinamide) possess distinct pharmacokinetic and risk profiles.
• Understanding these differences is crucial for effective dyslipidemia management and cardiovascular risk reduction.

Conclusions:

• Niacin remains a significant therapeutic option for comprehensive dyslipidemia management.
• Selection of the appropriate niacin formulation is critical for maximizing efficacy and minimizing adverse events.
• Further evaluation of specific niacin forms is necessary to guide clinical practice and optimize patient outcomes in cardiovascular risk reduction.